CN118302413A - 抗SARS-CoV-2药 - Google Patents
抗SARS-CoV-2药 Download PDFInfo
- Publication number
- CN118302413A CN118302413A CN202280074839.2A CN202280074839A CN118302413A CN 118302413 A CN118302413 A CN 118302413A CN 202280074839 A CN202280074839 A CN 202280074839A CN 118302413 A CN118302413 A CN 118302413A
- Authority
- CN
- China
- Prior art keywords
- mmol
- added
- compound
- ymsa
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-184512 | 2021-11-12 | ||
| JP2021184512 | 2021-11-12 | ||
| PCT/JP2022/042029 WO2023085392A1 (ja) | 2021-11-12 | 2022-11-11 | 抗ＳＡＲＳ－ＣｏＶ－２薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118302413A true CN118302413A (zh) | 2024-07-05 |
Family
ID=86335828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280074839.2A Pending CN118302413A (zh) | 2021-11-12 | 2022-11-11 | 抗SARS-CoV-2药 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250325547A1 (https=) |
| EP (1) | EP4431151A4 (https=) |
| JP (1) | JPWO2023085392A1 (https=) |
| CN (1) | CN118302413A (https=) |
| WO (1) | WO2023085392A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117362234A (zh) * | 2023-09-25 | 2024-01-09 | 苏州凯瑞医药科技有限公司 | 一种5-溴-7氯-1h吲唑的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007098047A2 (en) | 2006-02-16 | 2007-08-30 | The Mclean Hospital Corporation | Methods and compositions for the treatment of parkinson's disease |
| CN110214011A (zh) | 2017-01-19 | 2019-09-06 | 国立大学法人鹿儿岛大学 | 抗严重发热伴血小板减少综合征病毒的药物 |
| JP7176767B2 (ja) | 2017-04-13 | 2022-11-22 | 国立大学法人 鹿児島大学 | 新規なアモジアキン類似体およびその使用方法 |
| CN111303055B (zh) * | 2020-03-05 | 2021-12-24 | 中国农业科学院兰州畜牧与兽药研究所 | 喹唑啉衍生物及其制备方法和用途 |
| WO2021183463A1 (en) * | 2020-03-09 | 2021-09-16 | President And Fellows Of Harvard College | Compositions and methods for treating coronavirus |
| US20230346820A1 (en) * | 2020-05-05 | 2023-11-02 | The Scripps Research Institute | Methods and compositions for the treatment of sars-cov-2 |
| WO2021235390A1 (ja) * | 2020-05-18 | 2021-11-25 | 国立大学法人鹿児島大学 | 抗ＳＡＲＳ－ＣｏＶ－２薬 |
| JP2021184512A (ja) | 2020-05-21 | 2021-12-02 | 株式会社リコー | 画像形成装置 |
-
2022
- 2022-11-11 JP JP2023559919A patent/JPWO2023085392A1/ja active Pending
- 2022-11-11 CN CN202280074839.2A patent/CN118302413A/zh active Pending
- 2022-11-11 US US18/708,827 patent/US20250325547A1/en active Pending
- 2022-11-11 EP EP22892890.9A patent/EP4431151A4/en active Pending
- 2022-11-11 WO PCT/JP2022/042029 patent/WO2023085392A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4431151A4 (en) | 2025-02-26 |
| WO2023085392A1 (ja) | 2023-05-19 |
| EP4431151A1 (en) | 2024-09-18 |
| JPWO2023085392A1 (https=) | 2023-05-19 |
| US20250325547A1 (en) | 2025-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104470902B (zh) | N‑(3‑杂芳基芳基)‑4‑芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 | |
| CN107849037B (zh) | 用于治疗和预防乙型肝炎病毒感染的三环4-吡啶酮-3-甲酸衍生物 | |
| CN102977014B (zh) | 新的喹啉类化合物及其用途 | |
| WO2020221006A1 (zh) | 一种bet蛋白抑制剂、其制备方法及用途 | |
| JP2016535788A5 (https=) | ||
| AU2013326850B2 (en) | Novel compounds, their preparation and their uses | |
| US20220135567A1 (en) | Tyk2 pseudokinase ligands | |
| WO2013013614A1 (zh) | 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用 | |
| JP7035118B2 (ja) | ラクタム化合物誘導体およびその応用 | |
| JP2009500451A (ja) | ピラノピリジン化合物 | |
| KR20190028544A (ko) | 인간 pde1 억제제로서 유용한 트리아졸로피라지논 유도체 | |
| WO2005080392A1 (ja) | ピラゾロキノロン誘導体およびその用途 | |
| CN118302413A (zh) | 抗SARS-CoV-2药 | |
| CN118976029A (zh) | 用于预防或治疗帕金森病或非酒精性脂肪性肝炎的药学组合物 | |
| CN112204035A (zh) | 取代的3,4,12,12а-四氢-1Н-[1,4]噁嗪并[3,4-c]吡啶并[2,1-f][1,2,4]三嗪-6,8-二酮、其药物组合物、生产方法及用途 | |
| MX2015002046A (es) | Tris-(hetero)aril-pirazoles y su uso. | |
| CN108456214B (zh) | 含噁唑或咪唑结构的喹唑啉类化合物及其应用 | |
| CN114230630B (zh) | 雷公藤甲素衍生物及其应用 | |
| CN105646448B (zh) | 吡啶类化合物及其用途 | |
| CN101896492B (zh) | 四环双吡喃香豆素化合物及其抗hiv和抗结核菌用途 | |
| CN121466295A (zh) | eIF2α激酶调节剂在制备抗人冠状病毒药物中的应用 | |
| US10449186B2 (en) | Phenylethynyl-substituted benzenes and heterocycles for the treatment of cancer | |
| JP2001261675A (ja) | ピラゾリン誘導体またはテトラヒドロピリダジン誘導体を含有する医薬 | |
| JP2019519588A (ja) | ピリダジノンベースの広域スペクトル抗インフルエンザ阻害剤 | |
| TW202241428A (zh) | Ｓａｒｓ－ｃｏｖ－２所引起之病毒感染的方法及治療 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |